BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 19765730)

  • 1. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference.
    Xie B; Xing R; Chen P; Gou Y; Li S; Xiao J; Dong J
    J Surg Res; 2010 Aug; 162(2):231-8. PubMed ID: 19765730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of c-met-siRNA on the growth and invasion of hepatocellular carcinoma MHCC97-H cells].
    Xie B; Tang DG; Dong JH
    Zhonghua Gan Zang Bing Za Zhi; 2006 Jul; 14(7):499-504. PubMed ID: 16867270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The influence of downregulation of ezrin expression by RNA interference on the growth and metastasis of hepatocellular carcinoma: experiment in vitro].
    Zhang Y; Hu MY; Chen BH; Wang ZJ; Zha XL; Liu KD
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):530-5. PubMed ID: 16681881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells.
    Salvi A; Arici B; Portolani N; Giulini SM; De Petro G; Barlati S
    Int J Oncol; 2007 Aug; 31(2):451-60. PubMed ID: 17611703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasiveness of hepatocellular carcinoma cell lines: contribution of hepatocyte growth factor, c-met, and transcription factor Ets-1.
    Jiang Y; Xu W; Lu J; He F; Yang X
    Biochem Biophys Res Commun; 2001 Sep; 286(5):1123-30. PubMed ID: 11527416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.
    Salvi A; Sabelli C; Moncini S; Venturin M; Arici B; Riva P; Portolani N; Giulini SM; De Petro G; Barlati S
    FEBS J; 2009 Jun; 276(11):2966-82. PubMed ID: 19490101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells.
    Li N; Fu H; Tie Y; Hu Z; Kong W; Wu Y; Zheng X
    Cancer Lett; 2009 Mar; 275(1):44-53. PubMed ID: 19006648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibitory effect of blocking expression of human augmenter of liver regeneration (hALR) on proliferation of hepatocellular carcinoma cell line HepG2].
    Tang L; Sun H; Zhang L; Guo H; Zhang L; Liu Q
    Ai Zheng; 2006 Jun; 25(6):671-6. PubMed ID: 16764759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effects of ezrin on the proliferation and the invasiveness of cells of different hepatocellular carcinoma cell lines].
    Zhang Y; Hu MY; Chen BH; Wang ZJ; Wu WZ; Zhou K; Liu KD
    Zhonghua Gan Zang Bing Za Zhi; 2006 Jul; 14(7):489-94. PubMed ID: 16867268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hepatitis B virus X protein regulates c-met promoter via the ERKs singal pathway in HepG2 cells].
    Xie B; Tang C; Chen P; Gou YB; Yuan T; Jin SL; Zhou YY
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):531-4. PubMed ID: 19912689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Knocking down osteopontin expression by specific siRNA reduces the in vitro invasiveness of human hepatocellular carcinoma cells].
    Zhu XQ; Ye QH; Lei KF; Chen J; Qin LX
    Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):404-7. PubMed ID: 17152482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of FAK expression inhibition by RNA interference on liver cancer cells].
    Yuan Z; Zheng Q; Huang XY; Fan J
    Zhonghua Wai Ke Za Zhi; 2007 Oct; 45(19):1350-3. PubMed ID: 18241574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation.
    Sun CK; Man K; Ng KT; Ho JW; Lim ZX; Cheng Q; Lo CM; Poon RT; Fan ST
    Carcinogenesis; 2008 Nov; 29(11):2096-105. PubMed ID: 18765415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of CXCR3 in hepatocellular carcinoma].
    Shi M; Guo RP; Zhang CQ; Zhong C; Lin XJ; Li JQ
    Ai Zheng; 2006 Oct; 25(10):1232-7. PubMed ID: 17059766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of COX-2 gene silencing by shRNA on biological characteristics of human hepatocellular carcinoma cell line HepG2].
    Xu KS; Wang HF; Qian W; Wang BH
    Ai Zheng; 2007 Jan; 26(1):32-7. PubMed ID: 17222364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion.
    Kaufmann R; Oettel C; Horn A; Halbhuber KJ; Eitner A; Krieg R; Katenkamp K; Henklein P; Westermann M; Böhmer FD; Ramachandran R; Saifeddine M; Hollenberg MD; Settmacher U
    Carcinogenesis; 2009 Sep; 30(9):1487-96. PubMed ID: 19546160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells.
    Bessard A; Frémin C; Ezan F; Coutant A; Baffet G
    J Cell Physiol; 2007 Aug; 212(2):526-36. PubMed ID: 17427199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibition of SMYD3 gene expression by RNA interference induces apoptosis in human hepatocellular carcinoma cell line HepG2].
    Xu JY; Chen LB; Xu JY; Yang Z; Wei HY; Xu RH
    Ai Zheng; 2006 May; 25(5):526-32. PubMed ID: 16687068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expressions of the metastasis-associated factors of a new human hepatocellular carcinoma cell line with highly metastatic potential].
    Tian J; Tang Z; Xue Q
    Zhonghua Yi Xue Za Zhi; 1999 Jun; 79(6):470-2. PubMed ID: 11715447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experimental research of targeting hTERT gene inhibited in hepatocellular carcinoma therapy by RNA interference].
    Zhang PH; Tu ZG; Yang MQ; Huang WF; Zou L; Zhou YL
    Ai Zheng; 2004 Jun; 23(6):619-25. PubMed ID: 15191658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.